Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
VIM-1 carbapenemase-producing .

Ecology and evolution

Vittecoq M, Laurens C, Brazier L, Durand P, Elguero E, Arnal A, Thomas F, Aberkane S, Renaud N, Prugnolle F, Solassol J, Jean-Pierre H, Godreuil S, Renaud F.
PMID: 28303191
Ecol Evol. 2017 Jan 25;7(4):1224-1232. doi: 10.1002/ece3.2707. eCollection 2017 Feb.

Acquired carbapenemases currently pose one of the most worrying public health threats related to antimicrobial resistance. A NDM-1-producing

Cite
Vittecoq M, Laurens C, Brazier L, et al. VIM-1 carbapenemase-producing . Ecol Evol. 2017;7(4):1224-1232doi: 10.1002/ece3.2707.
Vittecoq, M., Laurens, C., Brazier, L., Durand, P., Elguero, E., Arnal, A., Thomas, F., Aberkane, S., Renaud, N., Prugnolle, F., Solassol, J., Jean-Pierre, H., Godreuil, S., & Renaud, F. (2017). VIM-1 carbapenemase-producing . Ecology and evolution, 7(4), 1224-1232. https://doi.org/10.1002/ece3.2707
Vittecoq, Marion, et al. "VIM-1 carbapenemase-producing ." Ecology and evolution vol. 7,4 (2017): 1224-1232. doi: https://doi.org/10.1002/ece3.2707
Vittecoq M, Laurens C, Brazier L, Durand P, Elguero E, Arnal A, Thomas F, Aberkane S, Renaud N, Prugnolle F, Solassol J, Jean-Pierre H, Godreuil S, Renaud F. VIM-1 carbapenemase-producing . Ecol Evol. 2017 Jan 25;7(4):1224-1232. doi: 10.1002/ece3.2707. eCollection 2017 Feb. PMID: 28303191; PMCID: PMC5305998.
Copy Download .nbib Format: NLM
Comparison of supervised classification methods for protein profiling in cancer diagnosis.

Cancer informatics

Dossat N, Mangé A, Solassol J, Jacot W, Lhermitte L, Maudelonde T, Daurès JP, Molinari N.
PMID: 19455249
Cancer Inform. 2007 Jul 19;3:295-305.

A key challenge in clinical proteomics of cancer is the identification of biomarkers that could allow detection, diagnosis and prognosis of the diseases. Recent advances in mass spectrometry and proteomic instrumentations offer unique chance to rapidly identify these markers....

Cite
Dossat N, Mangé A, Solassol J, et al. Comparison of supervised classification methods for protein profiling in cancer diagnosis. Cancer Inform. 2007;3:295-305
Dossat, N., Mangé, A., Solassol, J., Jacot, W., Lhermitte, L., Maudelonde, T., Daurès, J. P., & Molinari, N. (2007). Comparison of supervised classification methods for protein profiling in cancer diagnosis. Cancer informatics, 3295-305.
Dossat, Nadège, et al. "Comparison of supervised classification methods for protein profiling in cancer diagnosis." Cancer informatics vol. 3 (2007): 295-305.
Dossat N, Mangé A, Solassol J, Jacot W, Lhermitte L, Maudelonde T, Daurès JP, Molinari N. Comparison of supervised classification methods for protein profiling in cancer diagnosis. Cancer Inform. 2007 Jul 19;3:295-305. PMID: 19455249; PMCID: PMC2675844.
Copy Download .nbib Format: NLM
Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer.

Frontiers in oncology

Bellanger A, Le DT, Vendrell J, Wierinckx A, Pongor LS, Solassol J, Lachuer J, Clezardin P, Győrffy B, Cohen PA.
PMID: 34277402
Front Oncol. 2021 Jul 02;11:647269. doi: 10.3389/fonc.2021.647269. eCollection 2021.

Oncogene alternative splicing events can create distinct functional transcripts that offer new candidate prognostic biomarkers for breast cancer. ZNF217 is a well-established oncogene but its exon 4-skipping isoform (ZNF217-ΔE4) has never been investigated in terms of clinical or biological...

Cite
Bellanger A, Le DT, Vendrell J, et al. Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. Front Oncol. 2021;11:647269doi: 10.3389/fonc.2021.647269.
Bellanger, A., Le, D. T., Vendrell, J., Wierinckx, A., Pongor, L. S., Solassol, J., Lachuer, J., Clezardin, P., Győrffy, B., & Cohen, P. A. (2021). Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. Frontiers in oncology, 11647269. https://doi.org/10.3389/fonc.2021.647269
Bellanger, Aurélie, et al. "Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer." Frontiers in oncology vol. 11 (2021): 647269. doi: https://doi.org/10.3389/fonc.2021.647269
Bellanger A, Le DT, Vendrell J, Wierinckx A, Pongor LS, Solassol J, Lachuer J, Clezardin P, Győrffy B, Cohen PA. Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. Front Oncol. 2021 Jul 02;11:647269. doi: 10.3389/fonc.2021.647269. eCollection 2021. PMID: 34277402; PMCID: PMC8283766.
Copy Download .nbib Format: NLM
Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer.

Cancers

Fabbro M, Colombo PE, Leaha CM, Rouanet P, Carrère S, Quenet F, Gutowski M, Mourregot A, D'Hondt V, Coupier I, Vendrell J, Vilquin P, Pujol P, Solassol J, Mollevi C.
PMID: 32764409
Cancers (Basel). 2020 Aug 05;12(8). doi: 10.3390/cancers12082184.

No abstract available.

Cite
Fabbro M, Colombo PE, Leaha CM, et al. Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers (Basel). 2020;12(8)doi: 10.3390/cancers12082184.
Fabbro, M., Colombo, P. E., Leaha, C. M., Rouanet, P., Carrère, S., Quenet, F., Gutowski, M., Mourregot, A., D'Hondt, V., Coupier, I., Vendrell, J., Vilquin, P., Pujol, P., Solassol, J., & Mollevi, C. (2020). Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers, 12(8), . https://doi.org/10.3390/cancers12082184
Fabbro, Michel, et al. "Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer." Cancers vol. 12,8 (2020). doi: https://doi.org/10.3390/cancers12082184
Fabbro M, Colombo PE, Leaha CM, Rouanet P, Carrère S, Quenet F, Gutowski M, Mourregot A, D'Hondt V, Coupier I, Vendrell J, Vilquin P, Pujol P, Solassol J, Mollevi C. Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers (Basel). 2020 Aug 05;12(8). doi: 10.3390/cancers12082184. PMID: 32764409; PMCID: PMC7465919.
Copy Download .nbib Format: NLM
Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment.

Therapeutic advances in medical oncology

Vendrell JA, Quantin X, Serre I, Solassol J.
PMID: 33414847
Ther Adv Med Oncol. 2020 Dec 18;12:1758835920974192. doi: 10.1177/1758835920974192. eCollection 2020.

BACKGROUND: Histological transformation of advanced non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is one of the mechanisms of resistance to third-generation tyrosine kinase inhibitors (TKIs), such as osimertinib. This acquired TKI resistance is linked to...

Cite
Vendrell JA, Quantin X, Serre I, et al. Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment. Ther Adv Med Oncol. 2020;12:1758835920974192doi: 10.1177/1758835920974192.
Vendrell, J. A., Quantin, X., Serre, I., & Solassol, J. (2020). Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment. Therapeutic advances in medical oncology, 121758835920974192. https://doi.org/10.1177/1758835920974192
Vendrell, Julie A, et al. "Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment." Therapeutic advances in medical oncology vol. 12 (2020): 1758835920974192. doi: https://doi.org/10.1177/1758835920974192
Vendrell JA, Quantin X, Serre I, Solassol J. Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment. Ther Adv Med Oncol. 2020 Dec 18;12:1758835920974192. doi: 10.1177/1758835920974192. eCollection 2020. PMID: 33414847; PMCID: PMC7750569.
Copy Download .nbib Format: NLM
Evaluating .

Frontiers in pharmacology

Vendrell JA, Solassol J, Győrffy B, Vilquin P, Jarlier M, Donini CF, Gamba L, Maudelonde T, Rouanet P, Cohen PA.
PMID: 30740056
Front Pharmacol. 2019 Jan 25;9:1581. doi: 10.3389/fphar.2018.01581. eCollection 2018.

No abstract available.

Cite
Vendrell JA, Solassol J, Győrffy B, et al. Evaluating . Front Pharmacol. 2019;9:1581doi: 10.3389/fphar.2018.01581.
Vendrell, J. A., Solassol, J., Győrffy, B., Vilquin, P., Jarlier, M., Donini, C. F., Gamba, L., Maudelonde, T., Rouanet, P., & Cohen, P. A. (2018). Evaluating . Frontiers in pharmacology, 91581. https://doi.org/10.3389/fphar.2018.01581
Vendrell, Julie A, et al. "Evaluating ." Frontiers in pharmacology vol. 9 (2018): 1581. doi: https://doi.org/10.3389/fphar.2018.01581
Vendrell JA, Solassol J, Győrffy B, Vilquin P, Jarlier M, Donini CF, Gamba L, Maudelonde T, Rouanet P, Cohen PA. Evaluating . Front Pharmacol. 2019 Jan 25;9:1581. doi: 10.3389/fphar.2018.01581. eCollection 2018. PMID: 30740056; PMCID: PMC6355665.
Copy Download .nbib Format: NLM
High Nasal Carriage Rate of Staphylococcus aureus Containing Panton-Valentine leukocidin- and EDIN-Encoding Genes in Community and Hospital Settings in Burkina Faso.

Frontiers in microbiology

Ouedraogo AS, Dunyach-Remy C, Kissou A, Sanou S, Poda A, Kyelem CG, Solassol J, Bañuls AL, Van De Perre P, Ouédraogo R, Jean-Pierre H, Lavigne JP, Godreuil S.
PMID: 27679613
Front Microbiol. 2016 Sep 13;7:1406. doi: 10.3389/fmicb.2016.01406. eCollection 2016.

The objectives of the present study were to investigate the rate of S.aureus nasal carriage and molecular characteristics in hospital and community settings in Bobo Dioulasso, Burkina Faso. Nasal samples (n = 219) were collected from 116 healthy volunteers...

Cite
Ouedraogo AS, Dunyach-Remy C, Kissou A, et al. High Nasal Carriage Rate of Staphylococcus aureus Containing Panton-Valentine leukocidin- and EDIN-Encoding Genes in Community and Hospital Settings in Burkina Faso. Front Microbiol. 2016;7:1406doi: 10.3389/fmicb.2016.01406.
Ouedraogo, A. S., Dunyach-Remy, C., Kissou, A., Sanou, S., Poda, A., Kyelem, C. G., Solassol, J., Bañuls, A. L., Van De Perre, P., Ouédraogo, R., Jean-Pierre, H., Lavigne, J. P., & Godreuil, S. (2016). High Nasal Carriage Rate of Staphylococcus aureus Containing Panton-Valentine leukocidin- and EDIN-Encoding Genes in Community and Hospital Settings in Burkina Faso. Frontiers in microbiology, 71406. https://doi.org/10.3389/fmicb.2016.01406
Ouedraogo, Abdoul-Salam, et al. "High Nasal Carriage Rate of Staphylococcus aureus Containing Panton-Valentine leukocidin- and EDIN-Encoding Genes in Community and Hospital Settings in Burkina Faso." Frontiers in microbiology vol. 7 (2016): 1406. doi: https://doi.org/10.3389/fmicb.2016.01406
Ouedraogo AS, Dunyach-Remy C, Kissou A, Sanou S, Poda A, Kyelem CG, Solassol J, Bañuls AL, Van De Perre P, Ouédraogo R, Jean-Pierre H, Lavigne JP, Godreuil S. High Nasal Carriage Rate of Staphylococcus aureus Containing Panton-Valentine leukocidin- and EDIN-Encoding Genes in Community and Hospital Settings in Burkina Faso. Front Microbiol. 2016 Sep 13;7:1406. doi: 10.3389/fmicb.2016.01406. eCollection 2016. PMID: 27679613; PMCID: PMC5020597.
Copy Download .nbib Format: NLM
CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM.

Cancers

Belthier G, Homayed Z, Grillet F, Duperray C, Vendrell J, Krol I, Bravo S, Boyer JC, Villeronce O, Vitre-Boubaker J, Heaug-Wane D, Macari-Fine F, Smith J, Merlot M, Lossaint G, Mazard T, Portales F, Solassol J, Ychou M, Aceto N, Mamessier E, Bertucci F, Pascussi JM, Samalin E, Hollande F, Pannequin J.
PMID: 34638450
Cancers (Basel). 2021 Oct 02;13(19). doi: 10.3390/cancers13194966.

Circulating tumor cells (CTCs) are promising diagnostic and prognostic tools for clinical use. In several cancers, including colorectal and breast, the CTC load has been associated with a therapeutic response as well as progression-free and overall survival. However, counting...

Cite
Belthier G, Homayed Z, Grillet F, et al. CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM. Cancers (Basel). 2021;13(19)doi: 10.3390/cancers13194966.
Belthier, G., Homayed, Z., Grillet, F., Duperray, C., Vendrell, J., Krol, I., Bravo, S., Boyer, J. C., Villeronce, O., Vitre-Boubaker, J., Heaug-Wane, D., Macari-Fine, F., Smith, J., Merlot, M., Lossaint, G., Mazard, T., Portales, F., Solassol, J., Ychou, M., Aceto, N., Mamessier, E., Bertucci, F., Pascussi, J. M., Samalin, E., Hollande, F., & Pannequin, J. (2021). CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM. Cancers, 13(19), . https://doi.org/10.3390/cancers13194966
Belthier, Guillaume, et al. "CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM." Cancers vol. 13,19 (2021). doi: https://doi.org/10.3390/cancers13194966
Belthier G, Homayed Z, Grillet F, Duperray C, Vendrell J, Krol I, Bravo S, Boyer JC, Villeronce O, Vitre-Boubaker J, Heaug-Wane D, Macari-Fine F, Smith J, Merlot M, Lossaint G, Mazard T, Portales F, Solassol J, Ychou M, Aceto N, Mamessier E, Bertucci F, Pascussi JM, Samalin E, Hollande F, Pannequin J. CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM. Cancers (Basel). 2021 Oct 02;13(19). doi: 10.3390/cancers13194966. PMID: 34638450; PMCID: PMC8508506.
Copy Download .nbib Format: NLM
Proximal Protein Interaction Landscape of RAS Paralogs.

Cancers

Béganton B, Coyaud E, Laurent EMN, Mangé A, Jacquemetton J, Le Romancer M, Raught B, Solassol J.
PMID: 33187149
Cancers (Basel). 2020 Nov 11;12(11). doi: 10.3390/cancers12113326.

RAS proteins (KRAS, NRAS and HRAS) are frequently activated in different cancer types (e.g., non-small cell lung cancer, colorectal cancer, melanoma and bladder cancer). For many years, their activities were considered redundant due to their high degree of sequence...

Cite
Béganton B, Coyaud E, Laurent EMN, et al. Proximal Protein Interaction Landscape of RAS Paralogs. Cancers (Basel). 2020;12(11)doi: 10.3390/cancers12113326.
Béganton, B., Coyaud, E., Laurent, E. M. N., Mangé, A., Jacquemetton, J., Le Romancer, M., Raught, B., & Solassol, J. (2020). Proximal Protein Interaction Landscape of RAS Paralogs. Cancers, 12(11), . https://doi.org/10.3390/cancers12113326
Béganton, Benoît, et al. "Proximal Protein Interaction Landscape of RAS Paralogs." Cancers vol. 12,11 (2020). doi: https://doi.org/10.3390/cancers12113326
Béganton B, Coyaud E, Laurent EMN, Mangé A, Jacquemetton J, Le Romancer M, Raught B, Solassol J. Proximal Protein Interaction Landscape of RAS Paralogs. Cancers (Basel). 2020 Nov 11;12(11). doi: 10.3390/cancers12113326. PMID: 33187149; PMCID: PMC7696408.
Copy Download .nbib Format: NLM
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in .

Genes

Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, Thomas F, Geneviève D, Taourel P, Ychou M, Galibert V, Rideau C, Baudry K, Kogut Kubiak T, Coupier I, Hobeika R, Macary Y, Toledano A, Solassol J, Maalouf A, Daures JP, Pujol P.
PMID: 34356116
Genes (Basel). 2021 Jul 20;12(7). doi: 10.3390/genes12071100.

According to clinical guidelines, the occurrence of very early-onset breast cancer (VEO-BC) (diagnosed ≤ age 30 years) or VEO ovarian cancer (VEO-OC) (diagnosed ≤ age 40 years) in families with

Cite
Imbert-Bouteille M, Corsini C, Picot MC, et al. No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in . Genes (Basel). 2021;12(7)doi: 10.3390/genes12071100.
Imbert-Bouteille, M., Corsini, C., Picot, M. C., Mizrahy, L., Akouete, S., Huguet, H., Thomas, F., Geneviève, D., Taourel, P., Ychou, M., Galibert, V., Rideau, C., Baudry, K., Kogut Kubiak, T., Coupier, I., Hobeika, R., Macary, Y., Toledano, A., Solassol, J., Maalouf, A., Daures, J. P., & Pujol, P. (2021). No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in . Genes, 12(7), . https://doi.org/10.3390/genes12071100
Imbert-Bouteille, Marion, et al. "No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in ." Genes vol. 12,7 (2021). doi: https://doi.org/10.3390/genes12071100
Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, Thomas F, Geneviève D, Taourel P, Ychou M, Galibert V, Rideau C, Baudry K, Kogut Kubiak T, Coupier I, Hobeika R, Macary Y, Toledano A, Solassol J, Maalouf A, Daures JP, Pujol P. No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in . Genes (Basel). 2021 Jul 20;12(7). doi: 10.3390/genes12071100. PMID: 34356116; PMCID: PMC8305427.
Copy Download .nbib Format: NLM
EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.

Translational lung cancer research

Vendrell JA, Quantin X, Aussel A, Solassol I, Serre I, Solassol J.
PMID: 35004240
Transl Lung Cancer Res. 2021 Nov;10(11):4084-4094. doi: 10.21037/tlcr-21-679.

BACKGROUND: Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is highly selective for METHODS: Plasma samples from patients treated with osimertinib as a second-line therapy were collected and the presence of molecular alterations of...

Cite
Vendrell JA, Quantin X, Aussel A, et al. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome. Transl Lung Cancer Res. 2021;10(11):4084-4094doi: 10.21037/tlcr-21-679.
Vendrell, J. A., Quantin, X., Aussel, A., Solassol, I., Serre, I., & Solassol, J. (2021). EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome. Translational lung cancer research, 10(11), 4084-4094. https://doi.org/10.21037/tlcr-21-679
Vendrell, Julie A, et al. "EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome." Translational lung cancer research vol. 10,11 (2021): 4084-4094. doi: https://doi.org/10.21037/tlcr-21-679
Vendrell JA, Quantin X, Aussel A, Solassol I, Serre I, Solassol J. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome. Transl Lung Cancer Res. 2021 Nov;10(11):4084-4094. doi: 10.21037/tlcr-21-679. PMID: 35004240; PMCID: PMC8674606.
Copy Download .nbib Format: NLM
EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma.

International journal of molecular sciences

Szablewski V, Solassol J, Poizat F, Larrieux M, Crampette L, Mange A, Bascoul-Mollevi C, Costes V.
PMID: 23459231
Int J Mol Sci. 2013 Mar 04;14(3):5170-81. doi: 10.3390/ijms14035170.

Accumulation of molecular alterations, including EGFR overexpression and mutations in KRAS and BRAF, contribute to colorectal carcinogenesis. Since intestinal-type adenocarcinoma (ITAC) of the nasal cavity and paranasal sinus has morphologic and phenotypic features that are usually indistinguishable from colorectal...

Cite
Szablewski V, Solassol J, Poizat F, et al. EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. Int J Mol Sci. 2013;14(3):5170-81doi: 10.3390/ijms14035170.
Szablewski, V., Solassol, J., Poizat, F., Larrieux, M., Crampette, L., Mange, A., Bascoul-Mollevi, C., & Costes, V. (2013). EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. International journal of molecular sciences, 14(3), 5170-81. https://doi.org/10.3390/ijms14035170
Szablewski, Vanessa, et al. "EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma." International journal of molecular sciences vol. 14,3 (2013): 5170-81. doi: https://doi.org/10.3390/ijms14035170
Szablewski V, Solassol J, Poizat F, Larrieux M, Crampette L, Mange A, Bascoul-Mollevi C, Costes V. EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. Int J Mol Sci. 2013 Mar 04;14(3):5170-81. doi: 10.3390/ijms14035170. PMID: 23459231; PMCID: PMC3634474.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries